BiomX Inc. (NYSEAMERICAN:PHGE) Sees Significant Decline in Short Interest

BiomX Inc. (NYSEAMERICAN:PHGE) was the recipient of a significant decline in short interest in the month of February. As of February 13th, there was short interest totaling 133,660 shares, a decline of 50.6% from the January 29th total of 270,744 shares. Based on an average daily volume of 147,073 shares, the days-to-cover ratio is presently 0.9 days. Approximately 10.7% of the shares of the company are short sold. Approximately 10.7% of the shares of the company are short sold. Based on an average daily volume of 147,073 shares, the days-to-cover ratio is presently 0.9 days.

Institutional Trading of BiomX

An institutional investor recently bought a new position in BiomX stock. Citadel Advisors LLC acquired a new stake in BiomX Inc. (NYSEAMERICAN:PHGE) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 161,781 shares of the company’s stock, valued at approximately $85,000. Citadel Advisors LLC owned approximately 0.61% of BiomX as of its most recent filing with the Securities and Exchange Commission (SEC). 40.57% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating on shares of BiomX in a research report on Tuesday, November 25th. One investment analyst has rated the stock with a Buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $26.00.

BiomX Stock Down 4.4%

BiomX stock traded down $0.20 during midday trading on Friday, hitting $4.37. 31,756 shares of the company were exchanged, compared to its average volume of 103,131. The business has a fifty day simple moving average of $3.90 and a two-hundred day simple moving average of $6.74. BiomX has a fifty-two week low of $1.50 and a fifty-two week high of $14.71.

BiomX Company Profile

BiomX Inc is a clinical-stage biotechnology company that specializes in developing precision bacteriophage therapies to target pathogenic bacteria in the human microbiome. By harnessing the natural ability of bacteriophages to selectively infect and lyse harmful bacterial strains, BiomX aims to restore microbial balance without disrupting beneficial commensal organisms. The company’s platform integrates phage discovery, formulation and genetic engineering to create tailored phage cocktails for a range of microbiome-associated diseases.

The company’s pipeline includes lead clinical candidates for gastrointestinal disorders such as pouchitis and ulcerative colitis, as well as programs addressing dermatological indications including acne and atopic dermatitis.